Європейський Союз - словенська - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - gastrointestinalni stromalni tumorji - antineoplastična sredstva - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Європейський Союз - словенська - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - karcinom, pljučni pljuč - zdravila z delovanjem na novotvorbe in imunomodulatorji agenti, monoklonalna protitelesa - zdravilo nivolumab bms je indicirano za zdravljenje lokalno napredovalega ali metastatskega pljučnega raka nedrobnoceličnega pljuča (nsclc) po predhodni kemoterapiji pri odraslih.

Європейський Союз - словенська - EMA (European Medicines Agency)

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - vsi drugi terapevtski izdelki - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Європейський Союз - словенська - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastična sredstva - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - risperidon - orodisperzibilna tableta - risperidon 3 mg / 1 tableta - risperidon

Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - risperidon - orodisperzibilna tableta - risperidon 4 mg / 1 tableta - risperidon

Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva pharma b.v. - risperidon - orodisperzibilna tableta - risperidon 4 mg / 1 tableta - risperidon

Європейський Союз - словенська - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - zdravila za zdravljenje bolezni kosti - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

orodisperzibilna tableta - risperidon

Словенія - словенська - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

orodisperzibilna tableta - risperidon